ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology
Madeline Mayday, BS, a fourth-year Experimental Pathology graduate student in the Laboratory of Diane Krause, MD, PhD, was recently awarded a 2022 National Institute of Diabetes and Digestive and Kidney Diseases Hematology Centers Program Type B Pilot and Feasibility grant
Yale Pathologists Participating in Annual USCAP Meeting to Share Research, Advancements
Pathologists and research scientists from Department of Pathology at Yale School of Medicine will be involved in more than 40 presentations and sessions at the United States and Canadian Academy of Pathology (USCAP) 2022 Annual Meeting in Los Angeles March 19-24.
Harry Sanchez, MD, Welcomed to Cancer Signaling Networks Research Program at Yale Cancer Center
Harry Sanchez, MD, Assistant Professor of Pathology at Yale School of Medicine and Director of Yale Autopsy Services, was recently welcomed to the Cancer Signaling Networks Research Program at Yale Cancer Center.
Platelet response to influenza vaccination reflects effects of aging
A paper whose authors include several Yale School of Medicine professors, researchers and scientists recently made the cover of Aging Cell. The cover design is by Hannah Wang, Academic Support Associate, Department of Pathology.Source: Aging Cell
New Data Reported From Trials of Drug Developed at Yale Pathology to Treat Rare, Often Fatal Neonatal Disorder
Clinical trial data from an enzyme-therapy drug developed at Yale Pathology to treat a rare and often fatal neonatal calcification disorder were recently reported. The drug, INZ-701, was designed and validated in the laboratory of Demetrios Braddock, MD, PhD, Associate Professor of Pathology at Yale School of Medicine.
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape